Coronary risk factors in Kawasaki disease treated with additional gammaglobulin

M. Miura, H. Ohki, T. Tsuchihashi, Hiroyuki Yamagishi, Y. Katada, K. Yamada, Y. Yamashita, A. Sugaya, O. Komiyama, H. Shiro

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Aims: To assess the hypothesis that an additional intravenous gammaglobulin (IVGG) infusion, if administered early, may prevent coronary artery lesions (CAL) in patients with Kawasaki disease (KD) who do not respond to initial IVGG therapy. Methods: Forty four KD patients (17 with CAL and 27 without CAL), treated with additional IVGG because of persistent or recrudescent fever after initial IVGG therapy, were studied. Main outcome measures were the presence of CAL by echocardiography and the number of febrile days before and after start of additional IVGG infusion (pre- and post-additional IVGG). Results: In univariate analyses, risk factors for CAL were the number of febrile days pre-additional IVGG, the number of febrile days post-additional IVGG, the number of days that initial IVGG was divided over, the white blood cell count pre- and post-additional IVGG, and the C reactive protein concentration pre-additional IVGG. In a multivariate analysis, the only independent risk factor was the number of febrile days pre-additional IVGG (≥10 days; odds ratio 7.86; 95% Cl 1.44 to 42.8; p=0.02). Conclusions: Among KD patients with persistent or recrudescent fever after initial IVGG therapy, administration of additional IVGG before the first 10 febrile days was associated with a decreased prevalence of CAL, when compared with the prevalence in those who were retreated later. An additional IVGG infusion, if administered early, may prevent CAL in initial IVGG non-responders.

Original languageEnglish
Pages (from-to)776-780
Number of pages5
JournalArchives of Disease in Childhood
Volume89
Issue number8
DOIs
Publication statusPublished - 2004 Aug

Fingerprint

Mucocutaneous Lymph Node Syndrome
Coronary Vessels
Fever
Intravenous Infusions
Leukocyte Count
Intravenous Administration
C-Reactive Protein
Echocardiography
Therapeutics
Multivariate Analysis
Odds Ratio
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. / Miura, M.; Ohki, H.; Tsuchihashi, T.; Yamagishi, Hiroyuki; Katada, Y.; Yamada, K.; Yamashita, Y.; Sugaya, A.; Komiyama, O.; Shiro, H.

In: Archives of Disease in Childhood, Vol. 89, No. 8, 08.2004, p. 776-780.

Research output: Contribution to journalArticle

Miura, M, Ohki, H, Tsuchihashi, T, Yamagishi, H, Katada, Y, Yamada, K, Yamashita, Y, Sugaya, A, Komiyama, O & Shiro, H 2004, 'Coronary risk factors in Kawasaki disease treated with additional gammaglobulin', Archives of Disease in Childhood, vol. 89, no. 8, pp. 776-780. https://doi.org/10.1136/adc.2003.032748
Miura, M. ; Ohki, H. ; Tsuchihashi, T. ; Yamagishi, Hiroyuki ; Katada, Y. ; Yamada, K. ; Yamashita, Y. ; Sugaya, A. ; Komiyama, O. ; Shiro, H. / Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. In: Archives of Disease in Childhood. 2004 ; Vol. 89, No. 8. pp. 776-780.
@article{6a1fad31bc7a4da2ba490f654db33387,
title = "Coronary risk factors in Kawasaki disease treated with additional gammaglobulin",
abstract = "Aims: To assess the hypothesis that an additional intravenous gammaglobulin (IVGG) infusion, if administered early, may prevent coronary artery lesions (CAL) in patients with Kawasaki disease (KD) who do not respond to initial IVGG therapy. Methods: Forty four KD patients (17 with CAL and 27 without CAL), treated with additional IVGG because of persistent or recrudescent fever after initial IVGG therapy, were studied. Main outcome measures were the presence of CAL by echocardiography and the number of febrile days before and after start of additional IVGG infusion (pre- and post-additional IVGG). Results: In univariate analyses, risk factors for CAL were the number of febrile days pre-additional IVGG, the number of febrile days post-additional IVGG, the number of days that initial IVGG was divided over, the white blood cell count pre- and post-additional IVGG, and the C reactive protein concentration pre-additional IVGG. In a multivariate analysis, the only independent risk factor was the number of febrile days pre-additional IVGG (≥10 days; odds ratio 7.86; 95{\%} Cl 1.44 to 42.8; p=0.02). Conclusions: Among KD patients with persistent or recrudescent fever after initial IVGG therapy, administration of additional IVGG before the first 10 febrile days was associated with a decreased prevalence of CAL, when compared with the prevalence in those who were retreated later. An additional IVGG infusion, if administered early, may prevent CAL in initial IVGG non-responders.",
author = "M. Miura and H. Ohki and T. Tsuchihashi and Hiroyuki Yamagishi and Y. Katada and K. Yamada and Y. Yamashita and A. Sugaya and O. Komiyama and H. Shiro",
year = "2004",
month = "8",
doi = "10.1136/adc.2003.032748",
language = "English",
volume = "89",
pages = "776--780",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Coronary risk factors in Kawasaki disease treated with additional gammaglobulin

AU - Miura, M.

AU - Ohki, H.

AU - Tsuchihashi, T.

AU - Yamagishi, Hiroyuki

AU - Katada, Y.

AU - Yamada, K.

AU - Yamashita, Y.

AU - Sugaya, A.

AU - Komiyama, O.

AU - Shiro, H.

PY - 2004/8

Y1 - 2004/8

N2 - Aims: To assess the hypothesis that an additional intravenous gammaglobulin (IVGG) infusion, if administered early, may prevent coronary artery lesions (CAL) in patients with Kawasaki disease (KD) who do not respond to initial IVGG therapy. Methods: Forty four KD patients (17 with CAL and 27 without CAL), treated with additional IVGG because of persistent or recrudescent fever after initial IVGG therapy, were studied. Main outcome measures were the presence of CAL by echocardiography and the number of febrile days before and after start of additional IVGG infusion (pre- and post-additional IVGG). Results: In univariate analyses, risk factors for CAL were the number of febrile days pre-additional IVGG, the number of febrile days post-additional IVGG, the number of days that initial IVGG was divided over, the white blood cell count pre- and post-additional IVGG, and the C reactive protein concentration pre-additional IVGG. In a multivariate analysis, the only independent risk factor was the number of febrile days pre-additional IVGG (≥10 days; odds ratio 7.86; 95% Cl 1.44 to 42.8; p=0.02). Conclusions: Among KD patients with persistent or recrudescent fever after initial IVGG therapy, administration of additional IVGG before the first 10 febrile days was associated with a decreased prevalence of CAL, when compared with the prevalence in those who were retreated later. An additional IVGG infusion, if administered early, may prevent CAL in initial IVGG non-responders.

AB - Aims: To assess the hypothesis that an additional intravenous gammaglobulin (IVGG) infusion, if administered early, may prevent coronary artery lesions (CAL) in patients with Kawasaki disease (KD) who do not respond to initial IVGG therapy. Methods: Forty four KD patients (17 with CAL and 27 without CAL), treated with additional IVGG because of persistent or recrudescent fever after initial IVGG therapy, were studied. Main outcome measures were the presence of CAL by echocardiography and the number of febrile days before and after start of additional IVGG infusion (pre- and post-additional IVGG). Results: In univariate analyses, risk factors for CAL were the number of febrile days pre-additional IVGG, the number of febrile days post-additional IVGG, the number of days that initial IVGG was divided over, the white blood cell count pre- and post-additional IVGG, and the C reactive protein concentration pre-additional IVGG. In a multivariate analysis, the only independent risk factor was the number of febrile days pre-additional IVGG (≥10 days; odds ratio 7.86; 95% Cl 1.44 to 42.8; p=0.02). Conclusions: Among KD patients with persistent or recrudescent fever after initial IVGG therapy, administration of additional IVGG before the first 10 febrile days was associated with a decreased prevalence of CAL, when compared with the prevalence in those who were retreated later. An additional IVGG infusion, if administered early, may prevent CAL in initial IVGG non-responders.

UR - http://www.scopus.com/inward/record.url?scp=3242890566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242890566&partnerID=8YFLogxK

U2 - 10.1136/adc.2003.032748

DO - 10.1136/adc.2003.032748

M3 - Article

C2 - 15269082

AN - SCOPUS:3242890566

VL - 89

SP - 776

EP - 780

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

IS - 8

ER -